Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Redhill Biophrma ADR (RDHL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 180,157
  • Shares Outstanding, K 21,270
  • Annual Sales, $ 4,010 K
  • Annual Income, $ -45,540 K
  • 36-Month Beta 0.74
  • Price/Sales 43.59
  • Price/Cash Flow N/A
  • Price/Book 6.74

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.40
  • Number of Estimates 2
  • High Estimate -0.39
  • Low Estimate -0.40
  • Prior Year -0.90
  • Growth Rate Est. (year over year) +55.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.00 +21.00%
on 10/10/18
9.30 -8.92%
on 10/03/18
+0.47 (+5.88%)
since 09/19/18
3-Month
5.60 +51.25%
on 08/14/18
10.98 -22.86%
on 07/20/18
-1.88 (-18.16%)
since 07/19/18
52-Week
4.30 +96.98%
on 12/06/17
11.49 -26.28%
on 07/16/18
-0.31 (-3.53%)
since 10/19/17

Most Recent Stories

More News
Analysis: Positioning to Benefit within ScanSource, EMCORE, PRA Group, Aqua Metals, Compass Minerals International, and Redhill Biopharma -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of ScanSource, Inc. (NASDAQ:SCSC),...

RDHL : 8.57 (+1.18%)
SCSC : 37.44 (-0.76%)
PRAA : 30.93 (+0.26%)
CMP : 67.73 (+0.58%)
AQMS : 2.57 (-3.38%)
EMKR : 5.07 (-0.39%)
RedHill Biopharma Late-Breaking Abstract on Positive Phase III Crohn's Disease Study with RHB-104 to be Presented at UEG Week 2018

RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases,...

RDHL : 8.57 (+1.18%)
RedHill Biopharma to Present at Ladenburg Thalmann 2018 Healthcare Conference

RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases,...

RDHL : 8.57 (+1.18%)
RedHill Biopharma Announces Positive End-of-Phase II Meeting with FDA on BEKINDA(R) for IBS-D

-- The positive Type B meeting with the FDA followed a successful Phase II study of BEKINDA for diarrhea-predominant irritable bowel syndrome (IBS-D), one of the most common gastrointestinal disorders

RDHL : 8.57 (+1.18%)
RedHill Biopharma Announces Advancement to Second Stage of Phase IIa Study with YELIVA(R) for Cholangiocarcinoma

-- The first stage of the Phase IIa study with YELIVAfor advanced cholangiocarcinoma (bile duct cancer), a highly lethal malignancy, achieved its pre-specified efficacy goal, and the study can therefore...

RDHL : 8.57 (+1.18%)
RedHill Biopharma Announces Completion of Enrollment for Confirmatory Phase III Study with TALICIA(R) for H. pylori Infection

-- Top-line results from the randomized, double-blind confirmatory Phase III study (ERADICATE Hp2 study) with TALICIA are expected before year's end

RDHL : 8.57 (+1.18%)
RedHill Biopharma Reports Second Quarter 2018 Financial Results and Provides Update on Operations

Key Highlights:

RDHL : 8.57 (+1.18%)
RedHill Biopharma Ltd. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / August 30, 2018 / RedHill Biopharma Ltd. (NASDAQ: ) will be discussing their earnings results in their 2018 Second Quarter Earnings to be held on August 30, 2018 at 8:30 AM...

RDHL : 8.57 (+1.18%)
RedHill Biopharma to Host Second Quarter 2018 Financial Results Conference Call on August 30, 2018

RedHill Biopharma Ltd. (NASDAQ: RDHL) (Tel-Aviv Stock Exchange: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases,...

RDHL : 8.57 (+1.18%)
High Fiber Solutions Revenues to Aid Zayo (ZAYO) Q4 Earnings

Strong momentum in Fiber Solutions business and solid inorganic growth are likely to drive Zayo's (ZAYO) fiscal Q4 revenues although margin woes remain a concern.

RDHL : 8.57 (+1.18%)
BIG : 39.75 (-1.24%)
ZAYO : 31.95 (-0.09%)
FL : 47.38 (-2.91%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More Share

Trade RDHL with:

Business Summary

Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers...

See More

Key Turning Points

2nd Resistance Point 8.72
1st Resistance Point 8.60
Last Price 8.57
1st Support Level 8.25
2nd Support Level 8.02

See More

52-Week High 11.49
Fibonacci 61.8% 8.74
Last Price 8.57
Fibonacci 50% 7.89
Fibonacci 38.2% 7.05
52-Week Low 4.30

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar